onradivir
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2025 (NCT07229547)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 3 Sponsor(trial)
Mechanism of action
- Polymerase basic protein 2INHIBITOR
PB2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2n[nH]c3ncc(F)cc23)nc(C2CC2)c1F- Mol. weight
- 440.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095075 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07229547 | Phase 3 | Dec 1, 2025 | Jiao Tong University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1